retatrutide clinical trials safety Investigating the “efficacy and of retatrutide”, Eli Lilly saw " clinically meaningful weight loss” in a phase three trial ㅤ Go to the C+D website through the link 🔗in the bio Efficacy and safety of retatrutide,

Although the insulinotropic effect of GIP is diminished in patients with type 2 diabetes, studies have found that GIP receptor agonists can induce a degree of weight loss and, when used in combination with GLP-1, can produce synergistic effects, enhancing blood glucose reduction and weight loss

Constipation overlap

A full-dose, clinician-guided option with titration tailored to your body

A study shows that GLP-1 receptor agonists show a notably reduced incidence of primary open-angle glaucoma (POAG), ocular hypertension, and the requirement for first-line glaucoma treatments compared to metformin in individuals with type 2 diabetes (80)

Some providers recommend up to 10 minutes for maximum results

Prior authorization requirements add weeks to the approval process, delaying treatment initiation